The non-TZDselective PPARγ modulator INT131 is the culmination of amolecular target-based strategy to develop an improved insulin-sensitizing drugthat does not cause the weight gain and edema that plague the PPAR full agonists.As predicted by its unique PPARγ profile, INT131 shows potential as a potentand efficacious insulin-sensitizing molecule in T2DM patients that causeslittle if any weight gain at therapeutically efficacious doses. This evidence concerns the gene PPARA and type 2 diabetes mellitus.